Axon Enterprise, Inc (NASDAQ:AXON) Stake Boosted by Harel Insurance Investments & Financial Services Ltd.

Harel Insurance Investments & Financial Services Ltd. grew its holdings in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 52.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,968 shares of the biotechnology company's stock after buying an additional 3,101 shares during the quarter. Harel Insurance Investments & Financial Services Ltd.'s holdings in Axon Enterprise were worth $4,717,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the business. Vanguard Group Inc. increased its stake in Axon Enterprise by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 8,446,437 shares of the biotechnology company's stock valued at $5,019,886,000 after purchasing an additional 275,959 shares in the last quarter. Geode Capital Management LLC increased its stake in Axon Enterprise by 3.7% in the 4th quarter. Geode Capital Management LLC now owns 1,847,925 shares of the biotechnology company's stock valued at $1,095,542,000 after purchasing an additional 65,097 shares in the last quarter. Capital World Investors increased its stake in Axon Enterprise by 86.4% in the 4th quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock valued at $1,079,145,000 after purchasing an additional 841,772 shares in the last quarter. Alliancebernstein L.P. increased its stake in Axon Enterprise by 273.8% in the 4th quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company's stock valued at $659,128,000 after purchasing an additional 812,337 shares in the last quarter. Finally, Norges Bank purchased a new position in Axon Enterprise in the 4th quarter valued at approximately $482,081,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Axon Enterprise

In related news, Director Michael Garnreiter sold 5,913 shares of the business's stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $760.00, for a total value of $4,493,880.00. Following the transaction, the director owned 17,740 shares in the company, valued at approximately $13,482,400. The trade was a 25.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CRO Cameron Brooks sold 3,000 shares of the business's stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $740.76, for a total value of $2,222,280.00. Following the completion of the transaction, the executive owned 19,447 shares in the company, valued at approximately $14,405,559.72. This trade represents a 13.36% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 44,642 shares of company stock valued at $30,500,428 over the last 90 days. Corporate insiders own 4.40% of the company's stock.

Wall Street Analysts Forecast Growth

AXON has been the subject of several research analyst reports. Needham & Company LLC raised their price objective on Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Barclays boosted their price target on Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. Bank of America boosted their price target on Axon Enterprise from $750.00 to $895.00 and gave the stock a "buy" rating in a report on Wednesday, June 4th. Craig Hallum cut Axon Enterprise from a "buy" rating to a "cautious" rating in a report on Monday, March 10th. Finally, The Goldman Sachs Group boosted their price target on Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a report on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $699.55.

Axon Enterprise Trading Up 2.7%

Shares of NASDAQ:AXON traded up $20.93 during midday trading on Friday, reaching $795.48. The company's stock had a trading volume of 268,670 shares, compared to its average volume of 540,118. The firm has a market cap of $61.93 billion, a price-to-earnings ratio of 192.14, a price-to-earnings-growth ratio of 91.57 and a beta of 1.29. The company has a quick ratio of 2.62, a current ratio of 2.83 and a debt-to-equity ratio of 0.68. Axon Enterprise, Inc has a 1 year low of $279.02 and a 1 year high of $830.21. The business has a 50 day moving average price of $736.97 and a 200 day moving average price of $635.97.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.34 by $0.07. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The firm had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. During the same quarter in the previous year, the business earned $1.15 earnings per share. The firm's quarterly revenue was up 31.3% compared to the same quarter last year. Research analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current year.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.